Department of Internal Medicine, Lee's Endocrinology Clinic, Pingtung, Taiwan.
Diabetes Metab Res Rev. 2011 Sep;27(6):515-27. doi: 10.1002/dmrr.1201.
There are controversies regarding the association of visfatin with overweight/obesity, type 2 diabetes mellitus, insulin resistance (IR), metabolic syndrome and cardiovascular disease in published articles. A meta-analysis was performed to identify the significance of visfatin in these diseases. We searched for relevant articles in Pubmed, Scopus and SCIE. A total of 1035 articles were surveyed and 46 articles were identified, with 14 reports reporting more than one of our investigated diseases. A total of 13 (n = 644), 19 (n = 2405), 20 (n = 2249), 5 (n = 527) and 5 (n = 851) articles/(participants) were included in each meta-analysis regarding the association of visfatin and overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases, respectively. Plasma visfatin concentrations were increased in participants diagnosed with overweight/obesity, type 2 diabetes mellitus, metabolic syndrome and cardiovascular diseases, with pooled log odds ratios of 1.164 [95% confidence interval (CI): 0.348 to 1.981, p = 0.005], 1.981 (95% CI: 1.377 to 2.584, p < 0.001), 1.094 (95% CI: 0.678 to 1.511, p < 0.001), and 2.902 (95% CI: 0.924 to 4.879, p < 0.005), respectively. The circulating visfatin level was positively associated with insulin resistance, with a Fisher's z of 0.089 (95% CI: 0.013 to 0.165, p = 0.022). No single study was found to affect the overall result of each analysis by sensitivity testing. No publication bias was found by the Egger test. Our study suggests that the use of visfatin may be promising for predicting obesity, diabetes status, insulin resistance, metabolic syndrome and cardiovascular disease.
关于内脂素与超重/肥胖、2 型糖尿病、胰岛素抵抗（IR）、代谢综合征和心血管疾病的相关性，已发表的文章中存在争议。进行了荟萃分析以确定内脂素在这些疾病中的意义。我们在 Pubmed、Scopus 和 SCIE 中搜索了相关文章。共调查了 1035 篇文章，确定了 46 篇文章，其中 14 篇报告了我们调查的一种以上疾病。关于内脂素与超重/肥胖、2 型糖尿病、胰岛素抵抗、代谢综合征和心血管疾病的相关性，分别有 13 项（n = 644）、19 项（n = 2405）、20 项（n = 2249）、5 项（n = 527）和 5 项（n = 851）的研究/参与者被纳入荟萃分析。患有超重/肥胖、2 型糖尿病、代谢综合征和心血管疾病的参与者的血浆内脂素浓度升高，汇总的对数优势比分别为 1.164 [95%置信区间（CI）：0.348 至 1.981，p = 0.005]、1.981（95%CI：1.377 至 2.584，p < 0.001）、1.094（95%CI：0.678 至 1.511，p < 0.001）和 2.902（95%CI：0.924 至 4.879，p < 0.005）。循环内脂素水平与胰岛素抵抗呈正相关，Fisher's z 值为 0.089（95%CI：0.013 至 0.165，p = 0.022）。敏感性测试未发现任何单一研究影响每项分析的总体结果。Egger 检验未发现发表偏倚。我们的研究表明，内脂素的使用可能有望预测肥胖、糖尿病状态、胰岛素抵抗、代谢综合征和心血管疾病。
